New hope for Hard-to-Treat breast cancer: drug combo shows promise in trial

NCT ID NCT02860000

First seen Jan 10, 2026 · Last updated May 07, 2026 · Updated 13 times

Summary

This study tested a drug called alisertib, either alone or with another drug called fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responded to hormone therapy. The goal was to see if these treatments could shrink tumors. Alisertib works by blocking enzymes that help cancer cells grow, while fulvestrant blocks estrogen from fueling the cancer. The trial has completed, and results will help determine if this combination is a better option for controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee, 37204, United States

Conditions

Explore the condition pages connected to this study.